ASHA 624
Alternative Names: ASHA-624Latest Information Update: 28 Feb 2025
Price :
$50 *
At a glance
- Originator Asha Therapeutics
- Class Antiglaucomas; Neuroprotectants
- Mechanism of Action SARM1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Optic atrophy; Peripheral neuropathies
Most Recent Events
- 28 Feb 2025 Investigation in Peripheral neuropathies in USA (unspecified route) before February 2025 (Asha Therapeutics Pipeline, February 2025)
- 28 Feb 2025 Preclinical trials in Optic atrophy in USA (unspecified route) before February 2025 (Asha Therapeutics Pipeline, February 2025)
- 02 Apr 2024 Pharmacodynamic and adverse events data from a preclinical trial in Amyotrophic lateral sclerosis released by Asha Therapeutics